Anavar and Female Fertility: What Oxandrolone Does to Ovulation, Menstrual Cycles, and Reproductive Hormones

There is a conversation happening in private messages, in women-only forum threads, and in whispered questions at gym counters that almost never reaches the clinical literature or the content that ranks on Google. It is the conversation about what Anavar does to a woman’s ability to have children. Not what it does to her physique, her strength, or her voice. What it does to her ovaries, her menstrual cycle, and her future fertility. The bodybuilding world answers this with a shrug: “it’s mild, you’ll be fine.” The medical world answers it with a blanket warning: “androgens impair female reproduction.” Neither response is adequate, because neither provides the clinical data that a woman making this decision actually needs. A 2025 cross-sectional study at Imperial College London, the first to measure reproductive hormones in female AAS users with standardised blood panels, found that 83.3% of current users experienced menstrual irregularity and that FSH was suppressed to a median of 2.2 IU/L during active use (Hyams et al., 2025). The same study found that for the majority of past users, menstrual function had normalised after cessation. A long-term follow-up of the Dutch Turner Syndrome Oxandrolone Study, published in the European Journal of Endocrinology, tracked women into adulthood who had received oxandrolone during adolescence and found no lasting differences in breast development, Tanner staging, or virilisation between the oxandrolone and placebo groups (Menke et al., 2013). These two studies, taken together, define the clinical reality: Anavar and female fertility is not a story of permanent damage; it is a story of temporary disruption that resolves, provided the dose is low, the duration is short, and the user understands what is happening inside her body while it is happening. At Hemi Pharma UK, we consider this article among the most important we have published, because the women reading it deserve answers that are specific, evidence-based, and free of both false reassurance and unnecessary fear.

How Does the Female Reproductive Axis Work, and Where Does Anavar Interfere?

Understanding why Anavar disrupts fertility requires understanding what fertility depends on. The female reproductive cycle is orchestrated by a cascade of hormonal signals that must fire in precise sequence, at precise intervals, to produce a mature egg, release it from the ovary, and prepare the uterine lining for implantation. Any compound that disrupts this sequence at any point can prevent ovulation and, by extension, conception.

The cascade begins in the hypothalamus, which releases gonadotropin-releasing hormone (GnRH) in carefully timed pulses. These pulses stimulate the anterior pituitary to secrete two gonadotropins: follicle-stimulating hormone (FSH) and luteinising hormone (LH). FSH drives the development of ovarian follicles during the first half of the menstrual cycle. As the dominant follicle matures, it produces rising levels of oestradiol, which eventually triggers a surge in LH. The LH surge causes ovulation: the mature egg is released from the follicle and enters the fallopian tube, where fertilisation can occur. After ovulation, the collapsed follicle becomes the corpus luteum, which produces progesterone to maintain the uterine lining. If no embryo implants, progesterone drops, the lining sheds (menstruation), and the cycle restarts.

Oxandrolone enters this system as an exogenous androgen. Like all androgens, it provides negative feedback to the hypothalamus and pituitary, suppressing the pulsatile release of GnRH and consequently reducing FSH and LH secretion. The Hyams et al. (2025) study measured this directly: current AAS users had a median FSH of 2.2 IU/L (interquartile range 0.2 to 5.6), compared to 7.4 IU/L in past users who had ceased. Normal follicular-phase FSH ranges from approximately 3.5 to 12.5 IU/L. At 2.2 IU/L, FSH is too low to drive adequate follicular development. Without a maturing dominant follicle, oestradiol does not rise sufficiently to trigger the LH surge. Without the LH surge, ovulation does not occur. Without ovulation, pregnancy is impossible.

The mechanism is identical in principle to how hormonal contraceptives work: synthetic hormones suppress gonadotropin release to prevent ovulation. The difference is that contraceptives are designed for this purpose, with precisely calibrated doses and built-in withdrawal phases. Anavar suppresses ovulation as an unintended consequence of its androgenic activity, at doses that are not calibrated for this effect and without the cyclical withdrawal that maintains endometrial health.

What Does the Clinical Evidence Actually Show About Menstrual Disruption in Women Using AAS?

The Hyams et al. (2025) study at Imperial College London provides the strongest direct evidence. Among 6 current AAS users, 5 (83.3%) reported menstrual irregularity. Among 13 controls, only 2 (15.4%) reported irregularity. Among 9 past users who had stopped AAS, menstrual regularity had returned for the majority. Blood samples confirmed the hormonal basis: current users had suppressed FSH and altered reproductive hormone profiles, while past users showed recovery toward normal values.

This study is small but significant: it is the first to combine self-reported menstrual data with standardised reproductive hormone blood panels in female AAS users. Previous data consisted of qualitative reports and anecdotal evidence. Hyams et al. elevated the evidence from anecdote to measured biology.

A 2024 review in Annales d’Endocrinologie surveyed the broader evidence base and confirmed that perturbations of the menstrual cycle are common in female athletes using androgens, ranging from spaniomenorrhoea (infrequent menstruation, cycles longer than 35 days) to complete amenorrhoea (absence of menstruation for 3 or more consecutive months). The review noted that “data for their effects in women is lacking,” a statement that simultaneously acknowledges the disruption and laments the scarcity of controlled research (Annales d’Endocrinologie, 2024).

What the available data consistently shows is a dose-response relationship. At the therapeutic doses used in Turner syndrome studies (0.03 to 0.06 mg/kg/day, roughly 2mg to 4mg daily for a 60kg woman), menstrual disruption is mild and often indistinguishable from normal variation. At the bodybuilding doses typically used by women (5mg to 20mg daily), disruption becomes more common and more pronounced. At doses above 20mg daily or when multiple AAS are used concurrently, amenorrhoea is the expected outcome rather than a possible side effect.

What Do the Long-Term Follow-Up Studies Tell Us About Reversibility?

This is the question that matters most to women who want children in the future, and the evidence is genuinely reassuring.

The Dutch Turner Syndrome Oxandrolone Study (TOS) was a multicentre, double-blind, placebo-controlled trial that administered oxandrolone or placebo to girls with Turner syndrome alongside growth hormone therapy. The long-term follow-up, published by Menke et al. in the European Journal of Endocrinology in 2013, tracked 60 of the original participants into adulthood (mean follow-up approximately 9 years after the end of treatment). The study assessed adult height, body proportions, body composition, virilisation, metabolic markers, and reproductive development.

The key fertility-relevant findings: there were no significant differences in final breast size, Tanner staging, or signs of virilisation between women who had received oxandrolone and those who had received placebo. The height gain achieved during treatment was maintained into adulthood. The study concluded that previous oxandrolone treatment did not produce lasting adverse effects on sexual maturation or body composition in adult women.

A separate prospective study of oxandrolone in growth hormone-treated adolescent girls with Turner syndrome, published in Hormone Research in Paediatrics, found that by year 4 of the study, 71% of girls in the GH plus oxandrolone group had achieved menarche, compared to 65% in the GH plus placebo group. Breast development and menarche were “somewhat delayed” in the oxandrolone group during treatment, but there was no difference in pubic hair development or bone age progression after 4 years (Hormone Research in Paediatrics, 2021). The delay was transient, not permanent.

These studies examined girls receiving oxandrolone during the critical developmental window of puberty, when the reproductive axis is at its most vulnerable. If oxandrolone at therapeutic doses during adolescence does not produce lasting reproductive damage, the implication for adult women using it at comparable or slightly higher doses for short durations is strongly reassuring. The HPG axis of an adult woman whose reproductive system is already fully developed is more resilient to temporary androgen exposure than that of a developing adolescent.

Can You Get Pregnant While Taking Anavar?

It is unlikely but not impossible, and this distinction is critically important. Anavar is NOT a contraceptive. The gonadotropin suppression reduces the probability of ovulation but may not eliminate it entirely, particularly at low doses, during the first few days before full suppression is established, or in women with naturally high baseline gonadotropin levels. Women have conceived during AAS use. It is uncommon but documented.

If you are sexually active during an Anavar cycle and do not want to become pregnant, you must use reliable contraception. If you discover you are pregnant while taking Anavar, stop immediately. Oxandrolone is FDA pregnancy category X: it is known to cause foetal harm. Androgens cross the placenta and can cause virilisation of a female foetus (masculinisation of external genitalia: clitoral enlargement, labial fusion). This is a permanent, irreversible developmental effect. The critical window for genital development is weeks 8 to 12 of gestation, so stopping within the first trimester provides the best chance of avoiding virilisation. Inform your obstetrician of the exposure immediately.

How Long After Stopping Anavar Should You Wait Before Trying to Conceive?

Oxandrolone clears from the body within 48 to 72 hours of the last dose (5 half-lives at 9 hours). The drug itself is not the concern beyond this clearance window. The concern is the time required for the HPG axis to resume normal ovulatory cycling.

Based on the Hyams recovery data and the pharmacological half-life, a conservative recommendation is to wait for at least 2 to 3 complete, normal menstrual cycles after stopping Anavar before attempting conception. This typically means waiting 2 to 4 months after your last dose. During this waiting period, track your cycles using one or more of the following methods: calendar tracking (recording start dates and cycle length to confirm regularity has returned), basal body temperature charting (a sustained temperature rise of 0.2 to 0.5°C in the second half of the cycle confirms ovulation occurred), ovulation predictor kits (urine LH surge detection, available from any pharmacy), or mid-luteal progesterone blood test (a day-21 progesterone level above 30 nmol/L confirms ovulation in that cycle).

If your menstrual cycle has not returned within 12 weeks of stopping Anavar, or if it returns but remains irregular beyond 3 months, seek gynaecological evaluation. A reproductive hormone panel (FSH, LH, oestradiol, progesterone, AMH) and pelvic ultrasound to assess follicular development can identify where in the axis the recovery has stalled and guide intervention.

Is Anavar Safer for Fertility Than Other Steroids?

Based on pharmacological first principles and the available clinical data, yes, by a meaningful margin. Three properties make oxandrolone the least reproductively disruptive AAS for women.

First, its androgenic rating (24 vs testosterone’s 100) means the negative feedback signal to the hypothalamus and pituitary is weaker per milligram than any other commonly used AAS. At 5mg to 10mg daily, the total androgenic load is a fraction of what more potent compounds produce.

Second, it does not aromatise. Aromatising compounds (testosterone, Dianabol) add exogenous oestradiol that compounds the gonadotropin suppression through a second feedback pathway. Anavar avoids this.

Third, its 9-hour half-life allows rapid clearance and faster HPG axis recovery than long-acting injectables. Nandrolone decanoate’s 6-to-7-day half-life means its suppressive metabolites persist for weeks after the last injection, delaying recovery proportionally.

The Menke et al. (2013) long-term follow-up, showing no lasting reproductive effects from childhood oxandrolone exposure, provides the strongest longitudinal safety signal available for any AAS in women. No equivalent data exists for testosterone, nandrolone, stanozolol, or any other commonly used compound.

What Monitoring Should Women Do for Fertility Before, During, and After an Anavar Cycle?

Before the cycle

Baseline reproductive hormone panel: FSH, LH, oestradiol, progesterone (drawn on day 21 if possible to confirm ovulation), total testosterone, and SHBG. If AMH (anti-Müllerian hormone) is available, it provides a baseline measure of ovarian reserve that is independent of menstrual cycle phase and gonadotropin levels. Record your current cycle length, regularity, and flow pattern.

During the cycle

Menstrual tracking is the primary monitoring tool. Record any changes: longer or shorter cycles, missed periods, lighter or heavier flow, spotting between periods. These changes reflect the degree of gonadotropin suppression and ovulatory disruption. Blood tests for reproductive hormones are not routinely necessary during a short Anavar cycle (4 to 6 weeks) because the suppression is expected and temporary. Standard Anavar bloodwork (lipids, liver function, haematocrit) remains important as described in our Anavar bloodwork guide.

After the cycle

Track menstrual resumption. Most women using 5mg to 10mg daily for 4 to 6 weeks resume menstruation within 4 to 8 weeks. If amenorrhoea persists beyond 12 weeks, draw a reproductive hormone panel (FSH, LH, oestradiol, progesterone) to assess recovery. If FSH remains suppressed (below 3 IU/L) at 12 weeks post-cessation, referral to a reproductive endocrinologist is warranted, though this outcome is rare after short-duration, low-dose oxandrolone use.

Frequently Asked Questions

Will Anavar make me permanently infertile?

At the doses and durations used by women (5mg to 10mg daily for 4 to 6 weeks), permanent infertility from oxandrolone has not been documented in any clinical study. The Hyams et al. (2025) cross-sectional data showed recovery in the majority of past users. The Menke et al. (2013) long-term follow-up showed no lasting reproductive effects from childhood oxandrolone exposure extending into adulthood. Temporary suppression of ovulation is expected during active use. Permanent loss of fertility is not a documented outcome of short-term, low-dose oxandrolone in women with previously normal reproductive function.

Can I still get pregnant while on Anavar?

Unlikely but possible. Gonadotropin suppression reduces the probability of ovulation but does not guarantee it is eliminated, particularly at low doses and during the first days before full suppression is established. Anavar is NOT a contraceptive. If you are sexually active and do not want to conceive, use reliable contraception throughout and for at least one full menstrual cycle after stopping. If you discover a pregnancy during use, stop immediately: oxandrolone is FDA category X with documented risk of foetal virilisation.

Does the dose of Anavar affect how much it disrupts my cycle?

Yes. The relationship between dose and menstrual disruption is consistent across the clinical literature. At 2mg to 4mg daily (therapeutic range), disruption is minimal. At 5mg to 10mg daily (standard female bodybuilding range), some degree of cycle irregularity is common. At 15mg to 20mg daily, amenorrhoea is the expected outcome. Staying at the lowest effective dose for the shortest duration minimises the depth and duration of ovulatory suppression and accelerates recovery after cessation.

How long after stopping Anavar should I wait before trying to get pregnant?

Wait for at least 2 to 3 normal, confirmed ovulatory menstrual cycles after your last Anavar dose. This typically means 2 to 4 months. Confirm ovulation has resumed using basal body temperature charting, ovulation predictor kits, or a day-21 progesterone blood test. The 48-hour drug clearance time is not the limiting factor; the HPG axis recovery to normal ovulatory cycling is what determines when conception becomes possible and safe.

Should I freeze my eggs before using Anavar?

For a single low-dose, short-duration cycle (5mg to 10mg daily for 4 to 6 weeks), egg freezing is not clinically indicated. Short-term androgen exposure does not deplete the ovarian reserve (the total number of primordial follicles); it temporarily suppresses the maturation of those follicles through gonadotropin inhibition. The follicles are still there when the androgen is removed. For women planning multiple cycles over years, or cycles involving higher doses or more androgenic compounds, a fertility consultation including AMH testing to assess ovarian reserve before beginning is a reasonable precaution. The decision should be made with a reproductive endocrinologist who is informed about your planned compound use.